Free Trial
→ Satellite Images Spot Potential $10 Trillion Discovery (From Altimetry) (Ad)tc pixel Free AKRO Stock Alerts

This company has been marked as potentially delisted and may not be actively trading.

Akero Therapeutics (AKRO) Financials

Akero Therapeutics logo
Compare
Annual Income Statements for Akero Therapeutics

Annual Income Statements for Akero Therapeutics

This table shows Akero Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -44 -79 -101 -112 -152 -251
Consolidated Net Income / (Loss)		 -44 -79 -101 -112 -152 -252
Net Income / (Loss) Continuing Operations		 -44 -79 -101 -112 -152 -252
Total Pre-Tax Income 		-44 -79 -101 -112 -152 -252
Total Operating Income		 -46 -80 -101 -115 -173 -285
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 46 80 101 115 173 285
Selling, General & Admin Expense		 8.61 15 19 30 31 38
Research & Development Expense		 37 65 82 85 142 247
Total Other Income / (Expense), net		 1.90 0.95 0.11 3.12 21 33
Interest Expense		 - - 0.00 0.74 3.10 4.67
Interest & Investment Income		 - - 0.11 3.86 24 38
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)		 0.01 -0.00 0.02 -0.06 -0.23 -0.68
Basic Earnings per Share		 ($2.90) ($2.52) ($2.89) ($2.87) ($2.89) ($3.75)
Weighted Average Basic Shares Outstanding		 15.07M 31.46M 34.83M 38.98M 52.57M 67.14M
Diluted Earnings per Share		 ($2.90) ($2.52) ($2.89) ($2.87) ($2.89) ($3.75)
Weighted Average Diluted Shares Outstanding		 15.07M 31.46M 34.83M 38.98M 52.57M 67.14M
Weighted Average Basic & Diluted Shares Outstanding		 15.07M 31.46M 34.83M 46.97M 56.30M 79.62M
Cash Dividends to Common per Share		 $0.00 $0.00 $0.00 - $0.00 $0.00

Quarterly Income Statements for Akero Therapeutics

This table shows Akero Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025
Period end date 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025
Net Income / (Loss) Attributable to Common Shareholders		 -26 -31 -40 -54 -54 -56 -70 -71 -71 -71 -81
Consolidated Net Income / (Loss)		 -26 -31 -40 -55 -53 -56 -73 -70 -71 -71 -82
Net Income / (Loss) Continuing Operations		 -26 -31 -40 -55 -53 -56 -73 -70 -71 -71 -82
Total Pre-Tax Income 		-26 -31 -40 -55 -53 -56 -73 -70 -71 -71 -82
Total Operating Income		 -29 -36 -47 -62 -60 -66 -82 -78 -81 -81 -90
Total Gross Profit		 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Operating Expenses		 29 36 47 62 60 66 82 78 81 81 90
Selling, General & Admin Expense		 6.97 7.64 7.98 8.48 9.30 10 9.47 8.73 11 12 11
Research & Development Expense		 22 28 39 53 51 55 72 69 70 69 79
Total Other Income / (Expense), net		 2.92 4.55 6.96 6.69 6.61 9.75 9.00 8.00 10 10 8.67
Interest Expense		 0.46 0.86 0.89 0.90 0.99 1.23 1.25 1.20 1.15 1.17 2.65
Interest & Investment Income		 3.38 5.40 7.84 7.58 7.60 11 10 9.20 11 12 11
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)		 0.02 0.27 0.26 -0.78 0.35 0.18 -2.36 1.16 -0.14 0.10 -0.84
Basic Earnings per Share		 ($0.55) ($0.60) ($0.71) ($1.03) ($0.90) ($0.81) ($1.05) ($0.99) ($0.90) ($0.86) ($0.99)
Weighted Average Basic Shares Outstanding		 46.94M 51.87M 55.61M 52.57M 59.31M 69.16M 69.44M 67.14M 78.66M 81.72M 82.01M
Diluted Earnings per Share		 ($0.55) ($0.60) ($0.71) ($1.03) ($0.90) ($0.81) ($1.05) ($0.99) ($0.90) ($0.86) ($0.99)
Weighted Average Diluted Shares Outstanding		 46.94M 51.87M 55.61M 52.57M 59.31M 69.16M 69.44M 67.14M 78.66M 81.72M 82.01M
Weighted Average Basic & Diluted Shares Outstanding		 50.09M 55.60M 55.71M 56.30M 69.15M 69.43M 69.80M 79.62M 79.72M 79.99M 82.32M

Annual Cash Flow Statements for Akero Therapeutics

This table details how cash moves in and out of Akero Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Change in Cash & Equivalents		 -11 123 -37 99 -16 106
Net Cash From Operating Activities		 -36 -71 -80 -93 -145 -230
Net Cash From Continuing Operating Activities		 -36 -71 -80 -93 -145 -230
Net Income / (Loss) Continuing Operations		 -44 -79 -101 -112 -152 -252
Consolidated Net Income / (Loss)		 -44 -79 -101 -112 -152 -252
Depreciation Expense		 0.00 0.02 0.04 0.04 0.03 0.02
Amortization Expense		 -0.10 0.08 1.07 0.19 -9.11 -13
Non-Cash Adjustments To Reconcile Net Income		 1.77 6.08 10 24 22 31
Changes in Operating Assets and Liabilities, net		 6.46 2.22 9.73 -4.46 -6.33 3.00
Net Cash From Investing Activities		 -72 -9.76 42 -64 -224 -110
Net Cash From Continuing Investing Activities		 -72 -9.76 42 -64 -224 -110
Acquisitions		 - - - 0.00 0.00 -1.00
Purchase of Investments		 -72 -115 -44 -101 -433 -516
Sale and/or Maturity of Investments		 0.00 105 86 38 210 407
Net Cash From Financing Activities		 96 203 0.60 256 353 446
Net Cash From Continuing Financing Activities		 96 203 0.60 256 353 446
Repayment of Debt		 - - 0.00 0.00 0.00 0.00
Repurchase of Preferred Equity		 - - 0.00 0.00 0.00 0.00
Repurchase of Common Equity		 0.00 0.00 -0.52 -0.86 -0.78 -0.84
Issuance of Debt		 - - 0.00 10 15 10
Issuance of Common Equity		 96 203 0.37 241 336 424
Other Financing Activities, net		 0.45 0.36 0.75 5.02 3.27 13
Cash Interest Paid		 - - 0.00 0.44 2.48 3.98

Quarterly Cash Flow Statements for Akero Therapeutics

This table details how cash moves in and out of Akero Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025
Period end date 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025
Net Change in Cash & Equivalents		 8.11 186 -175 -35 390 -313 5.71 24 -154 35 -44
Net Cash From Operating Activities		 -25 -22 -50 -49 -35 -57 -70 -67 -68 -48 -67
Net Cash From Continuing Operating Activities		 -25 -22 -49 -49 -35 -57 -70 -67 -68 -48 -67
Net Income / (Loss) Continuing Operations		 -26 -31 -40 -55 -53 -56 -73 -70 -71 -71 -82
Consolidated Net Income / (Loss)		 -26 -31 -40 -55 -53 -56 -73 -70 -71 -71 -82
Amortization Expense		 -1.17 -1.26 -3.15 -3.53 -2.81 -3.29 -3.57 -2.84 -2.29 -2.67 -2.25
Non-Cash Adjustments To Reconcile Net Income		 5.06 5.07 6.06 5.61 7.88 8.71 7.47 7.34 8.88 9.18 10
Changes in Operating Assets and Liabilities, net		 -2.71 5.16 -13 3.93 13 -6.88 -1.61 -1.58 -3.54 16 6.26
Net Cash From Investing Activities		 18 -128 -126 13 58 -256 73 15 -482 79 57
Net Cash From Continuing Investing Activities		 18 -128 -126 13 58 -256 73 15 -482 79 57
Purchase of Investments		 -25 -189 -161 -58 -39 -339 -58 -80 -583 -76 -73
Sale and/or Maturity of Investments		 43 61 36 71 97 85 131 95 101 155 130
Net Cash From Financing Activities		 15 337 0.81 0.50 367 -0.15 3.07 76 396 3.43 -34
Net Cash From Continuing Financing Activities		 15 337 0.81 0.50 367 -0.15 3.07 76 396 3.43 -34
Repayment of Debt		 0.00 - - - 0.00 - - - 0.00 - -37
Other Financing Activities, net		 0.46 1.56 0.81 0.45 1.77 0.00 3.13 8.24 7.40 2.98 3.37
Cash Interest Paid		 0.28 0.67 0.77 0.77 0.77 1.09 1.09 1.03 0.98 1.00 1.24

Annual Balance Sheets for Akero Therapeutics

This table presents Akero Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2018 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Total Assets		 77 77 138 273 196 357 580 826
Total Current Assets		 77 77 138 271 194 355 560 770
Cash & Equivalents		 76 76 65 187 150 250 234 340
Short-Term Investments		 - - 72 81 38 102 316 403
Prepaid Expenses		 1.16 1.16 1.65 2.96 5.32 3.72 9.95 27
Plant, Property, & Equipment, net		 0.00 0.00 0.00 0.13 0.09 0.05 0.02 0.00
Total Noncurrent Assets		 0.02 0.02 0.07 1.86 1.88 1.35 20 56
Long-Term Investments		 - - - - - 0.00 19 55
Other Noncurrent Operating Assets		 0.02 0.02 0.07 1.86 1.88 1.35 1.01 0.76
Total Liabilities & Shareholders' Equity		 77 77 138 273 196 357 580 826
Total Liabilities		 2.34 2.34 9.39 15 26 30 45 76
Total Current Liabilities		 2.34 2.34 9.37 13 25 19 19 40
Accounts Payable		 1.37 1.37 0.95 3.43 6.71 7.97 7.04 9.03
Accrued Expenses		 0.97 0.97 8.42 9.68 18 11 12 31
Total Noncurrent Liabilities		 0.00 0.00 0.02 1.52 1.31 11 26 36
Long-Term Debt		 - - - - 0.00 9.54 25 35
Other Noncurrent Operating Liabilities		 0.00 0.00 0.02 1.52 1.31 1.38 0.87 0.72
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -50 -50 129 259 169 327 535 750
Total Preferred & Common Equity		 -50 -50 129 259 169 327 535 750
Total Common Equity		 -50 -50 129 259 169 327 535 750
Common Stock		 37 37 259 468 479 749 1,109 1,575
Retained Earnings		 -87 -87 -130 -210 -310 -422 -574 -826
Accumulated Other Comprehensive Income / (Loss)		 - - -0.01 -0.00 -0.03 0.04 0.27 0.95

Quarterly Balance Sheets for Akero Therapeutics

This table presents Akero Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025
Total Assets		 379 349 664 635 912 865 818 1,156 1,109 1,006
Total Current Assets		 378 347 643 576 911 776 747 713 765 755
Cash & Equivalents		 374 258 444 270 624 310 316 186 220 176
Short-Term Investments		 0.00 85 195 285 280 450 401 500 522 562
Prepaid Expenses		 3.94 4.27 3.76 21 7.62 16 30 27 22 17
Plant, Property, & Equipment, net		 0.06 0.04 0.03 0.02 0.02 0.02 0.02 0.00 0.00 0.00
Total Noncurrent Assets		 1.41 1.29 21 59 0.95 89 71 443 345 251
Long-Term Investments		 - - 19 58 0.00 88 70 442 344 250
Other Noncurrent Operating Assets		 1.41 1.29 1.13 1.07 0.95 0.88 0.82 0.69 0.62 0.55
Total Liabilities & Shareholders' Equity		 379 349 664 635 912 865 818 1,156 1,109 1,006
Total Liabilities		 36 42 47 52 66 67 79 72 83 48
Total Current Liabilities		 25 17 22 28 30 31 43 42 60 48
Accounts Payable		 6.01 7.08 10 11 14 15 25 11 13 20
Accrued Expenses		 19 9.60 11 15 16 17 18 25 34 27
Total Noncurrent Liabilities		 11 26 26 24 36 36 36 30 23 0.29
Long-Term Debt		 9.45 25 25 23 35 35 35 29 22 0.00
Other Noncurrent Operating Liabilities		 1.21 1.18 1.04 0.98 0.93 0.84 0.81 0.75 0.77 0.29
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 344 306 616 583 846 798 738 1,084 1,026 958
Total Preferred & Common Equity		 344 306 616 583 846 798 738 1,084 1,026 958
Total Common Equity		 344 306 616 583 846 798 738 1,084 1,026 958
Common Stock		 743 754 1,096 1,103 1,474 1,482 1,492 1,980 1,992 2,005
Retained Earnings		 -399 -448 -479 -519 -627 -683 -756 -897 -967 -1,049
Accumulated Other Comprehensive Income / (Loss)		 0.00 0.02 -0.25 -0.51 -0.08 -0.26 2.10 1.09 0.99 1.83

Annual Metrics And Ratios for Akero Therapeutics

This table displays calculated financial ratios and metrics derived from Akero Therapeutics' official financial filings.

Metric 2019 2020 2021 2022 2023 2024
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Growth Metrics		 - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 0.00% -80.37% -26.13% -15.18% -58.32% -63.74%
EBIT Growth		 0.00% -81.02% -27.37% -14.14% -50.12% -65.11%
NOPAT Growth		 0.00% -75.58% -25.87% -14.14% -50.12% -65.11%
Net Income Growth		 0.00% -81.02% -27.23% -11.17% -35.46% -66.09%
EPS Growth		 0.00% 13.10% -14.68% 0.69% -0.70% -29.76%
Operating Cash Flow Growth		 0.00% -98.74% -12.54% -16.11% -57.12% -58.29%
Free Cash Flow Firm Growth		 0.00% 0.00% -13.01% -38.05% -50.85% -54.24%
Invested Capital Growth		 0.00% -26.08% -97.92% 19.86% 41.20% -37.65%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% -2.48% 5.40% -28.08% -5.47%
EBIT Q/Q Growth		 0.00% 0.00% -2.70% 5.75% -26.72% -6.00%
NOPAT Q/Q Growth		 0.00% 0.00% -2.70% 5.75% -26.72% -6.00%
Net Income Q/Q Growth		 0.00% 0.00% -2.77% 7.71% -26.85% -6.25%
EPS Q/Q Growth		 0.00% 0.00% -1.05% 14.58% -25.65% 1.06%
Operating Cash Flow Q/Q Growth		 0.00% -19.89% -4.32% 1.27% -18.91% -8.72%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% -4.31% -14.18% -9.18%
Invested Capital Q/Q Growth		 0.00% 0.00% -16.39% 27.09% -79.85% 8.83%
Profitability Metrics		 - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 100.00% 100.00% 99.89% 97.29% 87.79% 88.31%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -43.00% -40.89% -47.11% -45.20% -35.22% -39.22%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -16.65% -40.89% -47.11% -45.20% -35.22% -39.22%
Return on Equity Simple (ROE_SIMPLE)		 -33.99% -30.62% -59.59% -34.31% -28.35% -33.60%
Net Operating Profit after Tax (NOPAT)		 -32 -56 -71 -81 -121 -200
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -8.65% -11.41% -13.21% -11.85% -6.94% -8.00%
Return On Investment Capital (ROIC_SIMPLE)		 - - - -23.98% -21.60% -25.44%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -44 -79 -101 -115 -173 -285
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -44 -79 -100 -115 -182 -298
Valuation Ratios		 - - - - - -
Price to Book Value (P/BV)		 4.92 3.46 4.36 7.85 2.43 2.59
Price to Tangible Book Value (P/TBV)		 4.92 3.46 4.36 7.85 2.43 2.59
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.03 0.05 0.05
Long-Term Debt to Equity		 0.00 0.00 0.00 0.03 0.05 0.05
Financial Leverage		 -1.06 -1.04 -1.07 -1.07 -1.03 -1.02
Leverage Ratio		 1.06 1.06 1.10 1.11 1.09 1.09
Compound Leverage Factor		 1.06 1.06 1.09 1.08 0.95 0.97
Debt to Total Capital		 0.00% 0.00% 0.00% 2.84% 4.46% 4.49%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 2.84% 4.46% 4.49%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 97.16% 95.54% 95.51%
Debt to EBITDA		 0.00 0.00 0.00 -0.08 -0.14 -0.12
Net Debt to EBITDA		 0.00 0.00 0.00 2.98 2.99 2.56
Long-Term Debt to EBITDA		 0.00 0.00 0.00 -0.08 -0.14 -0.12
Debt to NOPAT		 0.00 0.00 0.00 -0.12 -0.21 -0.18
Net Debt to NOPAT		 0.00 0.00 0.00 4.24 4.50 3.82
Long-Term Debt to NOPAT		 0.00 0.00 0.00 -0.12 -0.21 -0.18
Altman Z-Score		 39.25 35.85 13.86 49.65 16.11 13.90
Noncontrolling Interest Sharing Ratio		 61.28% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - -
Current Ratio		 14.73 20.70 7.70 18.61 29.27 19.38
Quick Ratio		 14.56 20.47 7.49 18.42 28.75 18.69
Cash Flow Metrics		 - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -54 -61 -84 -127 -196
Operating Cash Flow to CapEx		 0.00% -47,840.54% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 -114.22 -41.09 -42.07
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 -125.19 -46.91 -49.29
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 -125.19 -46.91 -49.29
Efficiency Ratios		 - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - -
Invested Capital		 -7.67 -9.68 -19 -15 -9.02 -12
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 -2.00 -9.47 3.80 6.32 -3.40
Enterprise Value (EV)		 497 627 550 2,221 756 1,179
Market Capitalization		 634 896 738 2,563 1,301 1,942
Book Value per Share		 $4.51 $7.45 $4.85 $6.98 $9.61 $10.75
Tangible Book Value per Share		 $4.51 $7.45 $4.85 $6.98 $9.61 $10.75
Total Capital		 129 259 169 336 560 785
Total Debt		 0.00 0.00 0.00 9.54 25 35
Total Long-Term Debt		 0.00 0.00 0.00 9.54 25 35
Net Debt		 -136 -268 -188 -342 -544 -763
Capital Expenditures (CapEx)		 0.00 0.15 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -7.72 -10 -20 -15 -9.18 -12
Debt-free Net Working Capital (DFNWC)		 129 258 168 336 541 731
Net Working Capital (NWC)		 129 258 168 336 541 731
Net Nonoperating Expense (NNE)		 12 23 30 31 31 52
Net Nonoperating Obligations (NNO)		 -136 -268 -188 -342 -544 -763
Total Depreciation and Amortization (D&A)		 -0.10 0.10 1.11 0.24 -9.08 -12
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($2.52) ($2.89) ($2.87) ($2.89) ($3.75)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 34.77M 35.01M 38.98M 52.57M 67.14M
Adjusted Diluted Earnings per Share		 $0.00 ($2.52) ($2.89) ($2.87) ($2.89) ($3.75)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 34.77M 34.83M 38.98M 52.57M 67.14M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($2.52) ($2.89) $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 31.46M 34.83M 46.97M 56.30M 79.62M
Normalized Net Operating Profit after Tax (NOPAT)		 -32 -56 -71 -81 -121 -200
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 -155.83 -55.78 -61.14
NOPAT to Interest Expense		 0.00 0.00 0.00 -109.08 -39.05 -42.80
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 -155.83 -55.78 -61.14
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 -109.08 -39.05 -42.80
Payout Ratios		 - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% -0.52% -0.77% -0.51% -0.33%

Quarterly Metrics And Ratios for Akero Therapeutics

This table displays calculated financial ratios and metrics derived from Akero Therapeutics' official financial filings.

Metric Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025
Period end date 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -15.46% -34.00% -38.29% -156.36% -109.84% -87.19% -71.36% -23.63% -32.51% -21.03% -8.46%
EBIT Growth		 -10.37% -29.12% -29.16% -143.40% -108.51% -84.52% -75.27% -26.11% -34.91% -23.02% -10.44%
NOPAT Growth		 -10.37% -29.12% -29.16% -143.40% -108.51% -84.52% -75.27% -26.11% -34.91% -23.02% -10.44%
Net Income Growth		 0.76% -13.43% -11.58% -139.33% -106.51% -80.12% -83.33% -26.89% -32.58% -25.93% -12.19%
EPS Growth		 25.68% 22.08% 22.83% -134.09% -63.64% -35.00% -47.89% 3.88% 0.00% -6.17% 5.71%
Operating Cash Flow Growth		 -7.68% -14.76% -101.91% -90.63% -42.66% -156.61% -41.64% -37.97% -92.56% 16.03% 4.62%
Free Cash Flow Firm Growth		 -695.16% -381.36% -135.44% -129.82% -18.39% -60.66% 0.15% -3.20% -101.10% 30.55% 5.10%
Invested Capital Growth		 34.92% 22.73% 76.16% 41.20% -84.40% 13.70% -171.54% -37.65% 30.83% -150.09% -125.20%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -17.25% -23.29% -34.94% -31.42% 4.03% -9.99% -23.53% 5.19% -2.87% -0.46% -10.70%
EBIT Q/Q Growth		 -13.11% -23.91% -30.83% -32.73% 3.10% -9.65% -24.28% 4.50% -3.66% 0.01% -11.58%
NOPAT Q/Q Growth		 -13.11% -23.91% -30.83% -32.73% 3.10% -9.65% -24.28% 4.50% -3.66% 0.01% -11.58%
Net Income Q/Q Growth		 -12.02% -20.33% -27.59% -39.15% 3.34% -4.95% -29.86% 3.69% -1.00% 0.31% -15.69%
EPS Q/Q Growth		 -25.00% -9.09% -18.33% -45.07% 12.62% 10.00% -29.63% 5.71% 9.09% 4.44% -15.12%
Operating Cash Flow Q/Q Growth		 3.43% 9.11% -122.07% 2.20% 27.74% -63.50% -22.58% 4.73% -0.86% 28.70% -39.23%
Free Cash Flow Firm Q/Q Growth		 -23.66% -12.91% -61.36% -2.00% 36.29% -53.22% -0.29% -5.42% -24.14% 47.09% -37.05%
Invested Capital Q/Q Growth		 20.10% -44.60% 71.70% -79.85% -150.57% 32.32% 10.97% 8.83% -25.92% -144.69% 19.83%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 89.84% 87.24% 85.08% 89.19% 88.97% 85.16% 88.99% 89.75% 87.44% 87.18% 90.39%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -49.39% -30.21% -25.82% -35.22% -31.11% -28.87% -35.90% -39.22% -27.92% -31.14% -34.53%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -49.39% -30.21% -25.82% -35.22% -31.11% -28.87% -35.90% -39.22% -27.92% -31.14% -34.53%
Return on Equity Simple (ROE_SIMPLE)		 -36.51% -18.74% -20.52% 0.00% -21.18% -25.58% -32.13% 0.00% -24.86% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -20 -25 -33 -43 -42 -46 -57 -55 -57 -57 -63
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -2.36% -1.53% -1.48% -2.68% -1.92% -1.38% -2.32% -2.36% -1.43% -1.48% -2.11%
Return On Investment Capital (ROIC_SIMPLE)		 - - - -7.73% - - - -6.95% -5.09% -5.40% -6.60%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -29 -36 -47 -62 -60 -66 -82 -78 -81 -81 -90
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -30 -37 -50 -65 -63 -69 -85 -81 -83 -84 -92
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 5.87 3.79 4.82 2.43 1.68 2.03 2.70 2.59 2.97 4.15 3.97
Price to Tangible Book Value (P/TBV)		 5.87 3.79 4.82 2.43 1.68 2.03 2.70 2.59 2.97 4.15 3.97
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.08 0.04 0.04 0.05 0.04 0.04 0.05 0.05 0.03 0.02 0.00
Long-Term Debt to Equity		 0.08 0.04 0.04 0.05 0.04 0.04 0.05 0.05 0.03 0.02 0.00
Financial Leverage		 -1.07 -1.05 -1.03 -1.03 -1.03 -1.02 -1.01 -1.02 -1.02 -1.03 -1.03
Leverage Ratio		 1.15 1.11 1.10 1.09 1.09 1.08 1.10 1.09 1.07 1.08 1.08
Compound Leverage Factor		 1.03 0.97 0.93 0.97 0.97 0.92 0.98 0.98 0.94 0.94 0.97
Debt to Total Capital		 7.44% 3.86% 4.09% 4.46% 3.95% 4.20% 4.54% 4.49% 2.59% 2.11% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.34% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 7.44% 3.86% 3.74% 4.46% 3.95% 4.20% 4.54% 4.49% 2.59% 2.11% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 92.56% 96.14% 95.91% 95.54% 96.05% 95.80% 95.46% 95.51% 97.41% 97.89% 100.00%
Debt to EBITDA		 -0.21 -0.19 -0.17 -0.14 -0.16 -0.14 -0.12 -0.12 -0.09 -0.07 0.00
Net Debt to EBITDA		 2.68 4.94 4.14 2.99 4.05 3.29 2.66 2.56 3.45 3.20 0.00
Long-Term Debt to EBITDA		 -0.21 -0.19 -0.16 -0.14 -0.16 -0.14 -0.12 -0.12 -0.09 -0.07 0.00
Debt to NOPAT		 -0.30 -0.28 -0.26 -0.21 -0.24 -0.21 -0.19 -0.18 -0.13 -0.10 0.00
Net Debt to NOPAT		 3.86 7.20 6.16 4.50 6.08 4.96 3.99 3.82 5.13 4.73 0.00
Long-Term Debt to NOPAT		 -0.30 -0.28 -0.24 -0.21 -0.24 -0.21 -0.19 -0.18 -0.13 -0.10 0.00
Altman Z-Score		 24.45 29.56 31.98 16.74 12.91 14.21 14.49 14.73 26.24 29.93 46.62
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 20.84 29.78 20.25 29.27 30.12 24.89 17.25 19.38 16.80 12.66 15.83
Quick Ratio		 20.58 29.60 19.50 28.75 29.86 24.39 16.57 18.69 16.17 12.29 15.48
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -27 -30 -49 -50 -32 -48 -49 -51 -64 -34 -46
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 -58.44 -35.19 -54.80 -55.33 -31.91 -39.36 -38.99 -42.68 -55.10 -28.71 -17.41
Operating Cash Flow to Interest Expense		 -53.90 -26.12 -55.99 -54.21 -35.46 -46.67 -56.52 -55.91 -58.63 -41.17 -25.36
Operating Cash Flow Less CapEx to Interest Expense		 -53.90 -26.12 -55.99 -54.21 -35.46 -46.67 -56.52 -55.91 -58.63 -41.17 -25.36
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -12 -18 -5.02 -9.02 -23 -15 -14 -12 -16 -38 -31
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 6.58 5.22 16 6.32 -10 2.43 -8.61 -3.40 6.97 -23 -17
Enterprise Value (EV)		 1,479 1,704 2,224 756 553 809 1,240 1,179 2,124 3,190 2,810
Market Capitalization		 1,797 2,339 2,812 1,301 1,422 1,622 1,992 1,942 3,223 4,254 3,798
Book Value per Share		 $6.52 $12.31 $10.49 $9.61 $15.03 $11.54 $10.63 $10.75 $13.61 $12.87 $11.97
Tangible Book Value per Share		 $6.52 $12.31 $10.49 $9.61 $15.03 $11.54 $10.63 $10.75 $13.61 $12.87 $11.97
Total Capital		 331 641 608 560 881 833 773 785 1,113 1,048 958
Total Debt		 25 25 25 25 35 35 35 35 29 22 0.00
Total Long-Term Debt		 25 25 23 25 35 35 35 35 29 22 0.00
Net Debt		 -319 -634 -588 -544 -869 -813 -752 -763 -1,099 -1,064 -988
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -12 -18 -5.12 -9.18 -23 -15 -14 -12 -16 -38 -31
Debt-free Net Working Capital (DFNWC)		 331 622 550 541 881 745 704 731 671 704 707
Net Working Capital (NWC)		 331 622 548 541 881 745 704 731 671 704 707
Net Nonoperating Expense (NNE)		 5.70 6.14 7.03 12 11 9.97 16 15 14 14 18
Net Nonoperating Obligations (NNO)		 -319 -634 -588 -544 -869 -813 -752 -763 -1,099 -1,064 -988
Total Depreciation and Amortization (D&A)		 -1.16 -1.25 -3.15 -3.52 -2.81 -3.29 -3.57 -2.82 -2.29 -2.67 -2.25
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.55) ($0.60) ($0.71) ($1.03) ($0.90) ($0.81) ($1.05) ($0.99) ($0.90) ($0.86) ($0.99)
Adjusted Weighted Average Basic Shares Outstanding		 46.94M 51.87M 55.61M 52.57M 59.31M 69.16M 69.44M 67.14M 78.66M 81.72M 82.01M
Adjusted Diluted Earnings per Share		 ($0.55) ($0.60) ($0.71) ($1.03) ($0.90) ($0.81) ($1.05) ($0.99) ($0.90) ($0.86) ($0.99)
Adjusted Weighted Average Diluted Shares Outstanding		 46.94M 51.87M 55.61M 52.57M 59.31M 69.16M 69.44M 67.14M 78.66M 81.72M 82.01M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 50.09M 55.60M 55.71M 56.30M 69.15M 69.43M 69.80M 79.62M 79.72M 79.99M 82.32M
Normalized Net Operating Profit after Tax (NOPAT)		 -20 -25 -33 -43 -42 -46 -57 -55 -57 -57 -63
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -62.92 -41.57 -52.49 -68.98 -60.50 -53.40 -65.57 -65.02 -70.09 -69.00 -34.06
NOPAT to Interest Expense		 -44.04 -29.10 -36.75 -48.28 -42.35 -37.38 -45.90 -45.51 -49.06 -48.30 -23.84
EBIT Less CapEx to Interest Expense		 -62.92 -41.57 -52.49 -68.98 -60.50 -53.40 -65.57 -65.02 -70.09 -69.00 -34.06
NOPAT Less CapEx to Interest Expense		 -44.04 -29.10 -36.75 -48.28 -42.35 -37.38 -45.90 -45.51 -49.06 -48.30 -23.84
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -1.03% -1.12% -0.76% -0.51% -0.42% -0.38% -0.36% -0.33% -0.43% -0.24% -0.21%

Financials Breakdown Chart

Key Financial Trends

Here are the key takeaways from Akero Therapeutics (AKRO) over the last four years, focusing on trends in cash flow, income, and the balance sheet through Q3 2025.

  • Liquidity runway: As of Q3 2025, Akero holds about $176.0M in cash and cash equivalents, $561.8M in short-term investments, and $250.5M in long-term investments, for a total asset base near $1.01B. This gives the company substantial liquidity to fund ongoing R&D and trials without immediate debt financing.
  • Significant early-2025 equity financing: In Q1 2025, Akero raised about $388.7M via issuance of common equity, with a smaller equity raise in Q2 2025. These inflows boost liquidity and reduce near-term financing risk.
  • Investing inflows help fund operations: Net cash from investing activities was positive in 2025 (Q2 +$79.3M, Q3 +$56.8M, and Q1 +$56.8M), driven by sale/maturity of investments. This provides cash support beyond ongoing operations and reduces reliance on debt.
  • Strong equity base on the balance sheet: Total Common Equity sits around $957.6M as of Q3 2025, indicating a solid capital cushion relative to liabilities.
  • Low or zero debt in recent periods: Long-term debt is essentially zero in Q3 2025 (with historically very modest debt levels in some periods), reducing near-term debt servicing risk.
  • Revenue remains non-existent: Total revenue is zero across reported quarters, meaning cash burn is not offset by product sales in the near term.
  • Dilution considerations: Shares outstanding have risen due to equity issuances, which has contributed to negative earnings per share in recent periods. This is a neutral factor for cash flow but relevant for long-term equity value.
  • Persistent net losses: Net income remains negative in every trailing period (e.g., Q3 2025 Consolidated Net Income = -$81.6M; Q2 2025 = -$70.5M; Q1 2025 = -$70.7M), reflecting ongoing R&D investment and operating expenses without revenue.
  • Operating cash burn persists: Net cash from operating activities is negative in all recent quarters (e.g., Q3 2025 = -$67.2M; Q2 2025 = -$48.2M; Q1 2025 = -$67.7M), signaling continued cash outflows from core operations.
  • High R&D expense driving losses: R&D outlays remain a primary driver of the cash burn (e.g., Q3 2025 RD expense = $78.9M; Q4 2024 RD expense = $69.3M), underscoring a pipeline-focused spend profile without revenue offset yet.
05/06/26 05:46 PM ETAI Generated. May Contain Errors.

Frequently Asked Questions About Akero Therapeutics' Financials

When does Akero Therapeutics' financial year end?

According to the most recent income statement we have on file, Akero Therapeutics' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Akero Therapeutics' net income changed over the last 5 years?

Akero Therapeutics' net income appears to be on an upward trend, with a most recent value of -$252.06 million in 2024, rising from -$43.76 million in 2019. The previous period was -$151.76 million in 2023. Check out Akero Therapeutics' forecast to explore projected trends and price targets.

What is Akero Therapeutics' operating income?
Akero Therapeutics' total operating income in 2024 was -$285.42 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $285.42 million
How has Akero Therapeutics' revenue changed over the last 5 years?

Over the last 5 years, Akero Therapeutics' total revenue changed from $0.00 in 2019 to $0.00 in 2024, a change of 0.0%.

How much debt does Akero Therapeutics have?

Akero Therapeutics' total liabilities were at $75.77 million at the end of 2024, a 68.5% increase from 2023, and a 3,135.4% increase since 2017.

How much cash does Akero Therapeutics have?

In the past 7 years, Akero Therapeutics' cash and equivalents has ranged from $64.79 million in 2019 to $340.24 million in 2024, and is currently $340.24 million as of their latest financial filing in 2024.

How has Akero Therapeutics' book value per share changed over the last 5 years?

Over the last 5 years, Akero Therapeutics' book value per share changed from 4.51 in 2019 to 10.75 in 2024, a change of 138.4%.


Related Companies

Financial statements for NASDAQ:AKRO last updated on 11/24/2025 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
The Iran War Just Broke the Gold Market
The Iran war isn't just a geopolitical event. It's a financial one. Within hours of the strikes, oil surged...
Behind the Markets | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
BlackRock, JPMorgan, and Goldman are all stock piling the same asset… are you?
BlackRock, JPMorgan, Goldman Sachs, Fidelity, ARK Invest and Andreessen Horowitz are all buying the same asset...
Awesomely, LLC | Sponsoredtc pixel
Military ‘Dark Energy’ to Power AI
When it was put inside U.S. tanks, they moved almost silently and produced no smoke. Now, Elon Musk is using t...
Altimetry | Sponsoredtc pixel
One executive order. The biggest wealth transfer of your lifetime.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Trump and Elon are BACK
15X Bigger Than SpaceX: Elon's New Launch While the rest of the market goes crazy for "the mother of all IP...
InvestorPlace | Sponsoredtc pixel